Coherus Q1 LOQTORZI rev $11.8M (+61% YoY); net loss $36.9M; pipeline readouts mid-2026

Coherus Oncology, Inc.

• LOQTORZI net revenue $11.8M in Q1 2026, up 61% YoY from $7.3M but down 5% from Q4 2025 $12.4M due to weather and seasonality.
• GAAP net loss from continuing ops $36.9M ($(0.27) diluted EPS) vs $47.4M ($(0.41)) in Q1 2025; non-GAAP net loss $33.9M ($(0.25)).
• Cash, cash equivalents and marketable securities $167.0M; Q1 equity offering of 32.89M shares raised net proceeds of $53.6M.
• Casdozokitug Phase 2 1L HCC fully enrolled, first data readout expected mid-2026; tagmokitug combo studies with initial data mid-2026 and 2H 2026.
• Q1 recorded highest new patient starts for LOQTORZI; average treatment duration growing; LOQTORZI remains only FDA-approved treatment for NPC.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.